New CAR T cell therapy using double target aimed at solid tumors

(University of Pennsylvania School of Medicine) Chimeric antigen receptors engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells. Researchers describe how an antibody that recognizes the combination of a known cancer-associated surface protein and a cancer-associated carbohydrate can be applied as a CAR-based therapy f...